AlphaGenome 2: Google DeepMind's model predicts how DNA changes affect specific cell types

Google DeepMind announced AlphaGenome 2 on November 11, 2026, a model that predicts how a DNA change plays out in a specific type of cell. Here is what it does and who can use it.

Google DeepMind announcement image for AlphaGenome 2

Every cell in your body carries the same DNA, yet a heart cell, an immune cell and a brain cell switch on different genes. That is why some genetic changes cause trouble only in one kind of cell. On November 11, 2026, Google DeepMind announced AlphaGenome 2, a model that predicts how a change in DNA plays out in a specific cell type.

You give the model a DNA sequence and the tissue or cell type you care about. It predicts how variants in that sequence change gene activity in that context. Google says it finds nearly twice as many variants linked to gene expression as the previous best model.

Key facts

  • Trained on more than 100 million individual cell profiles from 68 tissues.
  • Available now for non commercial research through the AlphaGenome API; commercial research is in private preview.
  • Google says it is for research only and not approved for clinical or diagnostic use.

What is new in version 2

  • Cell specific predictions. The first AlphaGenome predicted effects across tissues. Version 2 takes a target cell type or state as an input.
  • New data without retraining. Researchers can run it on fresh single cell data from a small set of cells.
  • Filling gaps. From one measured readout, it can predict others that were not measured.
  • DNA methylation joins the list of things it predicts.

The results Google reports

On an immune cell dataset called TenK10K, Google says AlphaGenome 2 found causal variants 30% of the time against 16% for comparison models, and the direction of gene effects 43% of the time against 23%. On COVID 19 vaccine data the model had not seen, it told activated T cells apart from resting ones.

Google is clear about the limit: the model helps researchers decide which variants to study first. Lab work still has to confirm them.

Who can use it

Researchers can use AlphaGenome 2 for non commercial work through the AlphaGenome API today, with Colab tutorials to start. Commercial research access is in private preview. Google is taking use case submissions until November 30, 2026 for possible extra quota and credits. Google has not published a price.

What it means for a small business

Unless you run a lab or a biotech startup, you will not use this model. If you sell to labs, clinics or health research teams, it is a sign of where their budgets and attention are going: AI that narrows thousands of candidates down to a short list before anyone touches a pipette. Supplements, wellness and genetic testing businesses should note Google's warning too. The model is not cleared for diagnosis, so nobody should market a product as backed by it.

Our take

AlphaGenome 2 is serious science with a narrow audience. For most owners, the interesting part is the pattern you see across this week's AI news: models that take a specific context as input and give a more targeted answer back.

Frequently asked questions

What is AlphaGenome 2?

AlphaGenome 2 is a Google DeepMind model, announced November 11, 2026, that predicts how DNA variants affect gene regulation in specific human cell types.

Can doctors use AlphaGenome 2 to diagnose patients?

No. Google says the models are for research only and have not been validated or approved for clinical or diagnostic use.

How do researchers get access?

Non commercial researchers can use it through the AlphaGenome API now. Commercial research access is in private preview.

Sources

More AI news

All AI news